MilliSpot, a porous polymer-based material for storing dry blood used in laboratory analyses, is a step closer to securing comprehensive patents.
The MilliSpot technology was developed at the University of Tasmania by Professor Emily Hilder and her research team at the Australian Centre for Research on Separation Science.
It extends the use of traditional paper-based materials for storing small quantities of blood and other samples involved in pharmaceutical drug development.
The MilliSpot materials provide a two to three times more sensitive response than can be achieved from paper.
The research team is working with UTAS commercialisation partner UniQuest to prepare the technology for a global market launch.
“[It is] an analytical materials technology that could help the pharmaceutical industry maximise a whole new range of operational and cost-saving benefits,” Dr Robin Fieldmouse says.
“There are also several other sizeable and attractive markets for MilliSpot-derived laboratory consumer products, including neo-natal heel prick tests [and] more advanced diagnostics.”
Given the huge scope of this technology, perhaps entrepreneurs should look at MilliSpot-derived lab consumer products in more detail.